Generation and activity of equine osteoclasts in vitro: Effects of the bisphosphonate pamidronate (APD)

Research in Veterinary Science

Volumn 72, Issue 2, 2002, Pages 105-113

  Gray, A W ^a   Davies, M E ^a   Jeffcott, L B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITONIN RECEPTOR; CALCIUM PHOSPHATE; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; VITRONECTIN RECEPTOR;

ANIMAL CELL; ARTICLE; BACTERIAL ARTHRITIS; BONE DISEASE; BONE LESION; BONE MARROW CULTURE; BONE TURNOVER; CELL ACTIVITY; CELL DEATH; CELL MATURATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HORSE; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; OSTEITIS; OSTEOARTHRITIS; OSTEOCLAST; OSTEOMYELITIS; OSTEOPOROSIS; PHENOTYPE; PROTEIN EXPRESSION;

EQUIDAE; EQUUS CABALLUS;

EID: 0036080656     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1053/rvsc.2001.0523     Document Type: Article

References (54)

1. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
2. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix
3. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group
4. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate
5. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro
6. Tartrate-resistant acid phosphatase in bone and cartilage following decalcification and cold-embedding in plastic
7. Septic osteitis of the distal phalanx: Findings and surgical treatment in 18 cases
8. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
9. +-ATPase
10. A new method to isolate large numbers of rabbit osteoclasts and osteoclast-like cells: Application to the characterization of serum response element binding proteins during osteoclast differentiation
11. Osteoclastic resorption of calcium phosphate ceramic thin films
12. The management of Paget's disease of bone
13. Biological activity of chicken calcitonin: Effects on neonatal rat and embryonic chick osteoclasts
14. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induce a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes, and osteoclasts in vivo
15. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease
16. In vitro generation of equine osteoclasts from bone marrow cells using a novel culture system
17. Equine osteoclast-like cells generated in vitro demonstrate similar characteristics to directly isolated mature osteoclasts
18. Calcium phosphate thin films to assay the effects of calcium-regulating hormones on the resorptive functions of osteoclasts
19. Surgical treatment of subchondral cystic lesions of the third metacarpal bone: Results in 15 horses (1986-1994)
20. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow
21. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
22. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
23. Technetium-99m methylene diphosphonate scintimammography for evaluation of palpable breast masses
24. Expression of the calcitonin receptor in bone marrow cell cultures and in bone: A specific marker of the differentiated osteoclast that is regulated by calcitonin
25. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro
26. Effects of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
27. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate
28. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras
29. Effects of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts
30. Equine pediatrics: Septic arthritis and osteomyelitis
31. A double-blind placebo-controlled trial of bisphosphonate in the treatment of navicular syndrome
32. Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function
33. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy
34. A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders
35. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts
36. Biochemical characterization of human osteoclast integrins
37. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures
38. Dose-response study of alendronate sodium for the treatment of cancer-associated hyperacalcaemia
39. Bisphosphonates stimulate the production of cytokines by human peripheral blood mononuclear cells in vitro
40. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
41. Alendronate treatment of naturally-occurring periodontitis in beagle dogs
42. Bisphosphonates: From the laboratory to the clinic and back again
43. Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption
44. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
45. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy
46. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
47. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: Inhibition by alendronate
48. Modulation of osteoclast differentiation
49. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
50. Aminohydroxybutane bisphosphate inhibits bone loss due to immobilization in rats
51. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption
52. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
53. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma
54. Acid extrusion is induced by osteoclast attachment to bone